

UC Glossary and Reference Citations

Glossary



ADC, antibody drug conjugate	mUC, metastatic urothelial carcinoma
ADCC, antibody-dependent cell-mediated cytotoxicity	mut/Mb, mutations per megabase
AEs, adverse events	NCCN, National Comprehensive Cancer Network
APNs, advanced practice nurses	NK cells, natural killer cells
BCOPs, board certified oncology pharmacists	NPs, nurse practitioners
BSA, body surface area	OCNs, oncology clinical nurses
BSC, best supportive care	ORR, objective response rate
CNSs, clinical nurse specialists	OS, overall survival
CPS, combined positive score	PAs, physician assistants
CR, complete response	PAX, paclitaxel
CS, corticosteroid(s)	PD-1, programmed death cell protein 1
CT, computed tomography	PD-L1, programmed death cell protein ligand 1
DOC, docetaxel	PET, positron emission tomography
Dx, diagnose(d)	PN, peripheral neuropathy
Dz, disease	pt(s), patient(s)
ECOG PS, Eastern Cooperative Oncology Group Performance Status	RECIST, Response Evaluation Criteria in Solid Tumors
ESMO, European Society for Medical Oncology	SOC, standard of care
FcR, crystallizable fragment region	TCs, tumor cells
FGFR, fibroblast growth factor receptor	TCS, topical corticosteroid(s)
GemCis, gemcitabine + cisplatin	TMB, tumor mutational burden
Hx, history	TUR, transurethral resection
ICs, immune cells	Tx, treatment/treated/therapy
ICI(s), immune checkpoint inhibitor(s)	UC, urothelial carcinoma
irAE(s), immune-related adverse event(s)	UTIs, urinary tract infections
IV, intravenous	VFL, vinflunine
mDOR, median duration of response	w/, w/o, with, without
MOA, mechanism of action	wks, weeks
mos, months	WHO, World Health Organization
mOS, median overall survival	
mPFS, median progression-free survival	

UC Glossary and Reference Citations

References

- Bellmunt J, Orsola A, Leow JJ, DeSantis M, Horwich A. Bladder Cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014;25(Suppl 3):iii40–iii48.
- Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med*. 2017;376:1015–1026.
- Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. *Hum Vaccin Immunother*. 2019;15:891–908.
- Ding X, Chen Q, Yang Z, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. *Cancer Manag Res*. 2019;11:4171–4184.
- Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. *Ann Transl Med*. 2019;7:690.
- ESMO Guidelines Committee. eUpdate — Bladder Cancer Treatment Recommendations. Published 16 December 2019. <https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations3>. Accessed August 13, 2020.
- Food and Drug Administration (FDA). FDA approves avelumab for urothelial carcinoma maintenance treatment. FDA press release. June 30, 2020. <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment>. Accessed August 13, 2020.
- Food and Drug Administration (FDA). FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. FDA press release. April 12, 2019. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma>. Accessed August 13, 2020.
- Food and Drug Administration (FDA). FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer. FDA press release. December 18, 2019. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer>. Accessed August 13, 2020.
- Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of immune-related adverse effects of immune checkpoint inhibitors: a review. *JAMA Oncol*. 2016;2:1346–1353.
- Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs—Part B: prostate and bladder tumours. *Eur Urol*. 2016;70:106–119.
- Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial cancer. *N Engl J Med*. 2019;381:338–348.
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Ann Oncol*. 2015;26:2375–2391.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 6.2020 — July 16, 2020. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed August 13, 2020.
- Petrylak DP. Immunotherapy: the wave of the future in bladder cancer? *Clin Genitourin Cancer*. 2017;15:S3–S17.
- Petrylak DP, Balar AV, O'Donnell PH, et al. EV-201: results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. *J Clin Oncol*. 2019;37(18 Suppl):4505.
- Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*. 2020; 383:1218–1230.
- Powles T, Walker J, Williams JA, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. *Cancer Treat Rev*. 2020;82:101925.
- Puzanov I, Diab A, Abdalla K. Managing toxicities associated with checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer Toxicity Management Working Group. *J Immunotherapy Cancer*. 2017;5:95.
- Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. *Ther Adv Urol*. 2019;11:1–7.
- Rosenberg JE, O'Donnell PH, Belar AF, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. *J Clin Oncol*. 2019;37:2592–2600.
- Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. *Rheumatology*. 2019;58(Suppl 7):vii7–vii916.
- Wang G, McKenney JK. Urinary bladder pathology: World Health Organization classification and American Joint Committee on Cancer Staging update. *Arch Pathol Lab Med*. 2019;143:571–577.
- Weber JS, Köhler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol*. 2012;30:2691–2697.